Recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) enhances healing and strength of granulation skin wounds.
A new animal model to study secondary intention wound healing and the effects of topically applied rhTGF-beta 1 was developed. A time course study was performed of full thickness 6 mm punch wounds placed on the backs of anesthetized pigs and treated once with either 3% methylcellulose or rhTGF-beta 1 in 3% methylcellulose or left untreated. Wounds receiving rhTGF-beta 1 had enhanced tensile strength at days 4 and 7 compared to controls. Studies of the response on days 4 and 7 to graded doses of rhTGF-beta 1 showed that a dose of 250 or 2500 ng rhTGF-beta 1 gave a similar enhanced wound strength, while 25 ng rhTGF-beta 1 had no effect. Blood flow to treated granulating wounds as measured by 141Ce microspheres indicate an increase in flow in wounds treated with 250, 500 or 2500 ng rhTGF-beta 1 compared to controls. These results indicate a possible use for rhTGF-beta 1 in enhancing wound healing clinically.
Beck
L S
LS
Research and Development, Genetech Inc., South San Francisco, California 94080.
Chen
T L
TL
Mikalauski
P
P
Ammann
A J
AJ
D000818:Animals; D004195:Disease Models, Animal; D006099:Granuloma / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000293:injuries*; D012883:Skin Ulcer / Q000188:drug therapy / Q000503:physiopathology; D013552:Swine; D013718:Tensile Strength; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta